Sorensen Mel
President and CEO
Sorensen Mel has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Aug 5, 2026.
On the most recent filing, Sorensen Mel is listed as President and CEO at Galera Therapeutics, Inc. Inside the rolling window, Sorensen Mel reported no open-market purchases and 1 open-market sale totaling $1K in GRTX.
Companies traded
Other insiders at GRTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Sorensen Mel made?
Sorensen Mel has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2025.
Which companies does Sorensen Mel trade?
Sorensen Mel has filed SEC Form 4 disclosures for 1 company, including GRTX.
When was Sorensen Mel's most recent SEC Form 4 filing?
Sorensen Mel's most recent SEC Form 4 filing on Tracefour is dated Aug 5, 2026.
What is Sorensen Mel's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Sorensen Mel is listed as President and CEO.
What is Sorensen Mel's total buy and sell value in the current window?
Inside the rolling retention window, Sorensen Mel bought $0 and sold $1K based on SEC Form 4 filings.
What was Sorensen Mel's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 70,000 GRTX shares on 2025-11-20, worth $1K, per SEC Form 4 filings.